Oramed Pharmaceuticals INC Schedule 13G passive stakes

Aquamarine Financial (Cayman) Ltd has filed a Schedule 13G, reporting beneficial ownership of 2,512,175 shares, representing 6.04% of Oramed Pharmaceuticals Inc.'s common stock.

BML Investment Partners, L.P. has reported a beneficial ownership of 2.5% in Oramed Pharmaceuticals Inc., holding 1,026,269 shares.

Aquamarine Financial (Cayman) Ltd has reported beneficial ownership of 2,047,652 shares, representing 5.06% of Oramed Pharmaceuticals Inc.'s common stock, as of January 14, 2026.

Oramed Pharmaceuticals Inc. has disclosed a 4.9% beneficial ownership stake in Scilex Holding Co., primarily through warrants and convertible notes.

BML Investment Partners, L.P. and Braden M. Leonard have reported beneficial ownership of 8.3% of Oramed Pharmaceuticals Inc. common stock.

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Co.

Oramed Pharmaceuticals Inc. has disclosed a 9.9% beneficial ownership stake in Scilex Holding Co, primarily through exercisable warrants.

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants, affirming a passive investment intent.

BML Investment Partners, L.P. has reported a 6.55% beneficial ownership stake in Oramed Pharmaceuticals Inc., holding 2,643,907 shares of common stock as of December 31, 2024.

Oramed Pharmaceuticals Inc. has reported a 6.2% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants.